Johnson & Johnson buys into bacteria for skin care

By Deanna Utroske

- Last updated on GMT

Johnson & Johnson buys into bacteria for skin care

Related tags Gut flora Skin Xycrobe therapeutics

The consumer side of J&J signed a research agreement, just last month, with Xycrobe Therapeutics to explore how engineered bacteria can be used in personal care and skin treatment products.

Based in LaJolla, California, Xycrobe Therapeutics is a biotech company that aims “to leverage the vast amount of data being generated from human microbiome research,” ​according the company splash page.

Critical relationships

Xycrobe Therapeutics is currently working with several commensal organism strains—that is bacteria that have a very close relationship with the human body. The company’s valuable asset is a “library” ​of bacteria “engineered to grow and secrete biotherapeutics as needed to help treat an array of skin issues,” ​according to a press release on the research agreement.

In partnership, J&J and Xycrobe will be investigating how this technology can be used commercially and therapeutically to address inflammatory skin conditions. Xycrobe expects that limiting inflammation with this biotheraperutic technology will have applications for acne, psoriasis, dermatitis, and eczema.

Scientific shift

Numerous companies, in and beyond the personal care industry, are at work on research involving the skin’s microbiome. Some are developing ingredients that are gentler and disrupt the body’s bacteria less than conventional ingredients do. Others are focused on restoring and maintaining the microbiome to what could be called its original state. And here, it seems that J&J’s new research may turn the microbiome into a sort of delivery mechanism for actives.

“The current paradigm for treating skin conditions, such as acne, completely disregards the importance of the commensal skin flora,” ​explains Thomas Hitchcock, Ph.D., founder and CEO of Xycrobe, in the press release. “We feel that the key to better treatment solutions for skin disease lies in understanding our body's interaction with the skin microbiome, and how we can leverage this information,” ​he adds.

Business is good

“Xycrobe's innovative technology and approach has great potential to change the way we think about how we treat acne and it's good to see a big player working with this emerging company,” ​says Hilary Baldwin, a member of the Xycrobe advisory board and medical doctor with the Acne Treatment Research Center, in the company’s press release about the deal with J&J.

Related topics Formulation & Science Skin Care

Related news

Show more

Related products

show more

Exosomes: Passing Trend or Transformative Reality?

Exosomes: Passing Trend or Transformative Reality?

Content provided by Naolys | 26-Mar-2024 | White Paper

Exosomes, microscopic vesicles naturally present in abundance within Plant Cells, have garnered significant attention within the scientific and cosmetic...

How Nutricosmetics Can Enhance Skin Beauty

How Nutricosmetics Can Enhance Skin Beauty

Content provided by Activ'Inside | 11-Dec-2023 | White Paper

In the ever-evolving realm of nutricosmetics, where inner wellness meets outer beauty, few natural ingredients have captured the spotlight quite like grapes.

Ultimate Antimicrobial Solution for BPC

Ultimate Antimicrobial Solution for BPC

Content provided by Acme-Hardesty Company | 11-Oct-2023 | White Paper

Sharomix™ EG10, a versatile broad-spectrum antimicrobial liquid blend for preserving personal care products, ensures safety at usage levels ranging from...

Acme-Hardesty Expands Product Line into Canada

Acme-Hardesty Expands Product Line into Canada

Content provided by Acme-Hardesty Company | 07-Jul-2023 | Product Brochure

Acme-Hardesty’s latest expansion into Canada includes Resplanta®, Botaneco®, and BYK from our partners Sharon Personal Care and Eckart Effect Pigments...

Related suppliers

Follow us


View more